secwatch.observer — SEC 8-K summary
======================================

Issuer:     TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK:        0000818686
Form:       8-K
Filed at:   2023-02-08T23:59:59+00:00
Accession:  0001157523-23-000205
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Teva reports FY2022 GAAP loss $2.12, non-GAAP EPS $2.52; Q4 rev $3.9B; guides 2023 lower
--------------------------------------------------------------------------------

- Full-year 2022 revenues $14.9B (-6% YoY); GAAP diluted loss per share $2.12; non-GAAP diluted EPS $2.52.
- Q4 2022 revenues $3.9B; GAAP diluted loss per share $1.10; non-GAAP diluted EPS $0.71.
- 2023 guidance: revenues $14.8-15.4B, non-GAAP diluted EPS $2.25-2.55, free cash flow $1.7-2.1B.
- Goodwill impairment charges of $2.045B and legal settlements of $2.082B recorded in 2022.
- CEO Richard Francis noted AUSTEDO US sales +20% YoY, generics in Europe +9% local currency.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818686/000115752323000205/0001157523-23-000205-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818686/000115752323000205/a53305953.htm
  HTML page:      https://secwatch.observer/filing/0001157523-23-000205

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer